Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 with chemotherapy in advanced cervical cancer
NCT06241235Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in Cervical Cancer (CC), sponsored by Zelgen. Started Mar 2024; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06241235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241235.